EXECUTIVE SUMMARY

A randomized controlled trial of Dilapan-S® vs Foley balloon for preinduction cervical ripening (DILAFOL trial)
Antonio F. Saad MD, Josephine Villarreal MD, Joe Eid MD, Nicholas Spencer MD, Viviana Ellis MD, Gary D. Hankins MD, George R. Saade MD

Objective:
- The objective of the study was to test the hypothesis that Dilapan-S® is not inferior to the Foley balloon for preinduction cervical ripening at term

Material and methods:
- The single-center randomized controlled trial ran from November 2016 to February 2018 at The University of Texas Medical Branch, Texas, USA
- 419 women were randomized (209 to Foley balloon; 210 to Dilapan-S®), all with 37th weeks or greater of gestation with an unfavorable cervix (≤3 cm dilated and ≤60% effaced)
- The primary outcome was proportion of vaginal delivery (%)
- Further evaluated parameters were focused on efficacy and safety aspects, as well as maternal satisfaction
- Maternal satisfaction was assessed using a survey (before and after preinduction period)

Results:
- Non-inferiority of Dilapan-S® vs Foley balloon in vaginal delivery rate was confirmed
- Vaginal delivery was more common in Dilapan-S® group vs Foley balloon (81.3% vs 76.1%)
- Both products showed highly safe profile with no safety issues
- Mothers with Dilapan-S® were statistically more satisfied than mothers with the Foley balloon as far as sleep, relaxing time and performance of desired daily activities

Key take away message:
- Dilapan-S® is non-inferior to the Foley balloon in terms of proportion of vaginal deliveries
- The results indicate trend to higher vaginal delivery rate and lower occurrence of C. section in Dilapan-S® group
- Median insertion time of 5 Dilapan-S® rods for 13 hours resulted in 87% cervical ripening success rate
- Minimal occurrence of adverse events with Dilapan-S® in both mothers and newborns
- Mothers with Dilapan-S® inserted were statistically more satisfied, as they could sleep, relax and perform daily activities without limitations
- Main advantages of Dilapan-S® over Foley catheter include FDA approval, safe profile, no protrusion from the introitus, no need to keep the device under tension and better maternal satisfaction